论文部分内容阅读
[目的]分析阿托品类散瞳药物预防青少年近视的疗效。[方法]-4.00 D以下的青少年近视56例(112眼),根据治疗前屈光度分为-0.50 D～-2.00 D和-2.25 D～-4.00 D两组。1%阿托品点眼每日1次连用3周后改为复方托品酰胺(0.25%托品酰胺加三磷酸腺苷10 mg)眼水,每晚睡前点眼1次用药半年以上。检查随访视力、屈光度、调节力等。[结果]治疗半年后裸眼视力提高2行以上的比率两组分别为73.43%和52.08%。屈光度下降-0.75 D±0.25 D的比率两组分别为75%和50%。治疗前后调节力相比,差异有统计学意义(P﹤0.01)。[结论]阿托品类散瞳药物点眼,通过抑制调节可以预防青少年近视的发展,尤其是-2.00D以下的低度近视。
[Objective] To analyze the efficacy of atropine mydriatic drug in the prevention of juvenile myopia. [Method] 56 cases (112 eyes) of juvenile myopia below -4.00 D were divided into two groups of -0.50 D ~ -2.00 D and -2.25 D ~ -4.00 D according to the refractive power before treatment. 1% atropine eye once daily for 3 weeks to compound propionamide (0.25% tropicamide plus adenosine triphosphate 10 mg) of eye water, eye drops every night before bedtime medication more than six months. Check the follow-up vision, refraction, accommodation and so on. [Results] After six months of treatment, the visual acuity increased more than two lines in the two groups were 73.43% and 52.08%. The diopter drop of -0.75 D ± 0.25 D was 75% and 50%, respectively, in both groups. Regulatory power before and after treatment, the difference was statistically significant (P <0.01). [Conclusions] Atropine mydriatic eye drops can prevent the development of juvenile myopia by inhibiting the regulation, especially the low myopia below -2.00D.